ArticleNature communications2018
Genomic patterns of progression in smoldering multiple myeloma.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07214324 (Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution), which is not on this map. Cited by 154 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
Who cites it
154 citing papers in PubMed, 2 syntheses or guidelines pooled it, 213 citations in OpenAlex.
- Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies.Blood cancer journal · 2025Pooled it
- Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.Human genomics · 2019Pooled it
- Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.Nature communications · 2026Trial
- Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry.Blood cancer discovery · 2026Article
- A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states.Nature genetics · 2026Article
- Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model.HemaSphere · 2026Article
- Smoldering multiple myeloma: advances in diagnosis and risk stratification, and evolving therapeutic strategies.International journal of hematology · 2026Review
- The Shape-Shifting Myeloma: Adaptive Plasticity as a Hallmark of Relapse and Refractoriness.Cancers · 2026Review
- Diagnosis, risk stratification and management of smouldering multiple myeloma.Nature reviews. Clinical oncology · 2026Review
- Whole-genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma.HemaSphere · 2026Article
- Review
- Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Genomics Define Malignant Transformation in Myeloma Precursor Conditions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Navigating the evolving management of smoldering multiple myeloma.HemaSphere · 2026Review
- Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.bioRxiv : the preprint server for biology · 2025Article
- Three-Dimensional Organization of Telomeres: An Emerging Prognostic Biomarker in Multiple Myeloma.Cells · 2025Review
- [Value of gene mutation in the prognosis and treatment of multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis.Clinical lymphoma, myeloma & leukemia · 2025Article
- Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma.Haematologica · 2025Article
- Article
94 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 4 countries.
Funding
Abstract
We analyzed whole genomes of unique paired samples from smoldering multiple myeloma (SMM) patients progressing to multiple myeloma (MM). We report that the genomic landscape, including mutational profile and structural rearrangements at the smoldering stage is very similar to MM. Paired sample analysis shows two different patterns of progression: a "static progression model", where the subclonal architecture is retained as the disease progressed to MM suggesting that progression solely reflects the time needed to accumulate a sufficient disease burden; and a "spontaneous evolution model", where a change in the subclonal composition is observed. We also observe that activation-induced cytidine deaminase plays a major role in shaping the mutational landscape of early subclinical phases, while progression is driven by APOBEC cytidine deaminases. These results provide a unique insight into myelomagenesis with potential implications for the definition of smoldering disease and timing of treatment initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.